Genzyme's Alemtuzumab for Treatment of Multiple Sclerosis Granted Fast Track Status by FDA
- Details
- Category: Genzyme
Genzyme Corporation (Nasdaq: GENZ) announced that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S. Food and Drug Administration (FDA).
Bristol-Myers Squibb Signs Agreements with ICON and PAREXEL
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) has signed agreements with ICON and PAREXEL, two leading providers of clinical development services to the biopharmaceutical industry, for joint strategic, operational and capability support of the company's clinical development program.
Trial of Nexavar® in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint
- Details
- Category: Bayer
Bayer HealthCare and Onyx Pharmaceuticals today announced that the final analysis of the Phase III NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar® (sorafenib) tablets in patients with advanced non-squamous, non-small cell lung cancer (NSCLC) showed that the trial did not meet its primary endpoint of improving overall survival in the first-line setting.
FDA advisory committee recommends approval of Novartis investigational treatment FTY720
- Details
- Category: Novartis
An advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease.
GSK drives Latin America growth strategy with acquisition of Laboratorios Phoenix
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (GSK) has acquired Laboratorios Phoenix S.A.C.yF ('Phoenix'), a leading Argentine pharmaceutical business, for a cash consideration of approximately $253 million.
AVERROES Study Closes Early Due to Clear Evidence of Efficacy
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation.
Ranbaxy Launches Antiplatelet Agent Prasugrel in India
- Details
- Category: Daiichi Sankyo
Daiichi Sankyo Company Limited ("Daiichi Sankyo") and Ranbaxy Laboratories Limited ("Ranbaxy") announced today that Ranbaxy has launched a generic version of prasugrel in India. The product, called Prasita, is an antiplatelet agent for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
More Pharma News ...
- Americans Are Not Taking Action to Protect Themselves Against Muscle Loss
- Sanofi Pasteur Partners with Vivalis for the Discovery of Human Monoclonal Antibodies
- Merck Resubmits U.S. Application for Cladribine Tablets
- Phase III study showed Avastin-based regimen helped women with advanced ovarian cancer
- Phase 3 Study Showed MACUGEN® Improved Vision Over Standard of Care
- Merck Announces Launch of Pioneering Collaborative Cancer Trials Network
- FDA Approves Amgen's Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women with Osteoporosis